A detailed history of Insight Advisors, LLC transactions in Amgen Inc stock. As of the latest transaction made, Insight Advisors, LLC holds 2,007 shares of AMGN stock, worth $634,031. This represents 0.17% of its overall portfolio holdings.

Number of Shares
2,007
Previous 2,013 0.3%
Holding current value
$634,031
Previous $579,000 1.55%
% of portfolio
0.17%
Previous 0.2%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 06, 2024

SELL
$268.87 - $324.56 $1,613 - $1,947
-6 Reduced 0.3%
2,007 $570,000
Q4 2023

Jan 23, 2024

BUY
$255.7 - $288.46 $15,086 - $17,019
59 Added 3.02%
2,013 $579,000
Q3 2023

Nov 07, 2023

SELL
$218.65 - $271.46 $168,797 - $209,567
-772 Reduced 28.32%
1,954 $525,000
Q2 2023

Aug 07, 2023

SELL
$214.27 - $253.37 $5,356 - $6,334
-25 Reduced 0.91%
2,726 $605,000
Q1 2023

May 03, 2023

BUY
$225.79 - $275.2 $14,676 - $17,888
65 Added 2.42%
2,751 $665,000
Q4 2022

Feb 21, 2023

BUY
$229.03 - $291.01 $1,832 - $2,328
8 Added 0.3%
2,686 $705,000
Q3 2022

Dec 12, 2022

BUY
$224.46 - $253.15 $2,469 - $2,784
11 Added 0.41%
2,678 $604,000
Q2 2022

Aug 11, 2022

BUY
$230.71 - $256.74 $461 - $513
2 Added 0.08%
2,667 $659,000
Q1 2022

May 13, 2022

BUY
$219.27 - $242.57 $219 - $242
1 Added 0.04%
2,665 $644,000
Q4 2021

Feb 09, 2022

BUY
$198.88 - $227.6 $2,187 - $2,503
11 Added 0.41%
2,664 $599,000
Q3 2021

Nov 12, 2021

SELL
$212.27 - $248.7 $11,674 - $13,678
-55 Reduced 2.03%
2,653 $570,000
Q2 2021

Aug 12, 2021

SELL
$233.58 - $259.14 $29,664 - $32,910
-127 Reduced 4.48%
2,708 $649,000
Q1 2021

May 17, 2021

SELL
$221.91 - $258.6 $43,494 - $50,685
-196 Reduced 6.47%
2,835 $679,000
Q4 2020

Feb 12, 2021

BUY
$216.38 - $257.67 $655,847 - $780,997
3,031 New
3,031 $697,000

Others Institutions Holding AMGN

About AMGEN INC


  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $169B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Insight Advisors, LLC Portfolio

Follow Insight Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Insight Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Insight Advisors, LLC with notifications on news.